Articles
Research Articles:
2026
-
- Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling. Krishna A, Meynert A, Dolt KS, Kelder M, Mesropian A, Ewing A, Brouwers C, Claassens JW, Linssen MM, Sheraz S, Taylor GC, Gautier P, Ferrer-Vaquer A, Grimes G, Becher H, Silk R, Gris-Oliver A, Pinyol R, Semple CA, Kendall TJ, Bird TG, Hadjantonakis AK, Marsh JA, Llovet JM, Hohenstein P, Wood AJ, Ozdemir DD. Nat Genet. 2026. doi: 10.1038/s41588-025-02496-5
- Activated ATF6α is a hepatic tumour driver restricting immunosurveillance. Li X, Lebeaupin C, Kadianaki A, Druelle-Cedano C, Vesper N, Rennert C, Huguet-Pradell J, Gomez Ramos B, Fan C, Piecyk RS, Zizmare L, Ramadori P, Li L, Frick L, Qiu M, Zhang C, Martins Nascentes Melo L, Ranvir VP, Shen P, Hanselmann J, Kosla J, Fernández-Vaquero M, Vucur M, Baskaran P, Bao X, Coleman OI, Tang Y, Cetin M, Chen Z, Jang I, Del Prete S, Rahbari M, Zhang P, Pham TV, Hou Y, Sun A, Gu L, Kim LC, Rothermel U, Heide D, Ali A, Gallage S, Talvard-Balland N, Piqué-Gili M, Gris-Oliver A, Bevilacqua A, Schlicker L, Duffey A, Unger K, Szydlowska M, Hetzer J, Odom DT, Machauer T, Bucci D, Sant P, Lee JH, Rösler J, Meckelmann SW, Schreck J, Murray S, Simon MC, Nahnsen S, Schulze A, Ho PC, Jugold M, Breuhahn K, Mallm JP, Schirmacher P, Roth S, Rahbari N, Tschaharganeh DF, Roessler S, Goeppert B, Bengsch B, Andrieux G, Boerries M, Malek NP, Prinz M, Weber A, Zeiser R, Tamayo P, Bronsert P, Kurowski K, Thimme R, Yuan D, Carretero R, Luedde T, Pinyol R, Hartmann FJ, Karin M, Tasdogan A, Trautwein C, Mall M, Hofmann M, Llovet JM, Haller D, Kaufman RJ, Heikenwälder M. Nature. 2026. doi: 10.1038/s41586-025-10036-8.
- Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection. Bashiardes S, Heinemann M, Adlung L, Valdés-Mas R, Mahdi JA, Nobs SP, Tuganbaev T, Yamada T, Horn M, Mor U, Cohen Y, Israel S, Korem M, Oster Y, Olshtain-Pops K, Orenbuch-Harroch E, Arslan MD, Molina S, Zur M, Eliyahu-Miller S, Bukimer A, Federici S, Dori-Bachash M, Amar N, Elbirt D, Cohen-Poradosu R, Turner D, Hershcovici T, Vainer E, Stettner N, Harmelin A, Gebremeskel H, Kebede Y, Schmidt S, Zmora N, Dhamodaran A, Puschhof J, Bentwich Z, Shapiro H, Amit I, Elinav H, Elinav E. Nat Microbiol. 2026. doi: 10.1038/s41564-025-02253-8.
- Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling. Krishna A, Meynert A, Dolt KS, Kelder M, Mesropian A, Ewing A, Brouwers C, Claassens JW, Linssen MM, Sheraz S, Taylor GC, Gautier P, Ferrer-Vaquer A, Grimes G, Becher H, Silk R, Gris-Oliver A, Pinyol R, Semple CA, Kendall TJ, Bird TG, Hadjantonakis AK, Marsh JA, Llovet JM, Hohenstein P, Wood AJ, Ozdemir DD. Nat Genet. 2026. doi: 10.1038/s41588-025-02496-5
2025
-
- Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim G, Kim C, Chon HJ. Liver Cancer. 2025. doi: 10.1159/000549565.
- Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. Balaseviciute U, Huguet-Pradell J, Abril-Fornaguera J, Gris-Oliver A, Rialdi A, Fernández-Martínez E, Montironi C, Del Pozo V, Houghton P, Zanatto L, Mesropian A, Keraite I, Thung S, Armengol C, Sancho-Bru P, Guccione E, Pinyol R, Llovet JM. Mol Oncol. 2025. doi: 10.1002/1878-0261.70168.
- Strategies to address non-proportional hazards between survival curves – Lessons from phase III trials in hepatocellular carcinoma. Mauro E, de Castro T, Zeitlhoefler M, Hackshaw A, Lee M, Meyer T, Singal AG, Llovet JM. J Hepatol. 2026;84(3):567-577. doi: 10.1016/j.jhep.2025.08.042.
- Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma. Seraphin TP, Mesropian A, Žigutytė L, Brooks J, Mauro E, Gris-Oliver A, Pinyol R, Montironi C, Balaseviciute U, Piqué-Gili M, Huguet-Pradell J, van Treeck M, Kallenbach M, Schneider AT, Roderburg C, Kather JN, Luedde T, Llovet JM. JHEP Rep. 2025. doi: 10.1016/j.jhepr.2025.101592.
- E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. Mesropian A, Gris-Oliver A, Balaseviciute U, Potdar AA, Kimura T, Shen J, Torres-Marcén M, Abril-Fornaguera J, Piqué-Gili M, Camell-Raventos D, Peix J, Fernández-Martínez E, Huguet-Pradell J, Hernández de Sande A, Keraite I, Esteban-Fabró R, Bárcena-Varela M, Lindblad KE, Lujambio A, Guccione E, Thung S, Ikeda M, Kudo M, Sia D, Pinyol R, Llovet JM. Clin Cancer Res. 2025;31(23):5037-5050. doi: 10.1158/1078-0432.CCR-25-0725.
- Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma. Li S, Motiño O, Lambertucci F, Pol J, Chen H, Pan L, Durand S, Rossin F, Campani C, Poupel L, Klein C, Montégut L, Pérez-Lanzón M, Anagnostopoulos G, Nogueira-Recalde U, Cerone A, Aprahamian F, Dong Y, Lizarralde-Guerrero M, Xue E, Liu P, Zhao L, Pan H, Carbonnier V, Lachkar S, Saavedra Díaz EG, Sun L, Desdouets C, Colnot S, Kepp O, Martins I, Zitvogel L, Piacentini M, Nault JC, Maiuri MC, Zucman-Rossi J, Kroemer G. Cell Rep Med. 2025. doi: 10.1016/j.xcrm.2025.102232.
- Intratumour ploidy heterogeneity and clonal evolution in hepatocellular carcinoma. Cordier P, Hirsch TZ, Caruso S, Pan L, Galy-Fauroux I, Klein C, De La Cruz-Ojeda P, Maille P, Poupel L, Imbeaud S, Zucman-Rossi J, Calderaro J, Desdouets C. J Hepatol. 2025. doi: 10.1016/j.jhep.2025.11.015.
- Targeting ATR to overcome cisplatin resistance in hepatoblastoma. Morel-Ribeiro P, Cornet M, Pilet J, Asif-Laidin A, Schaeffer S, Bourdeaux D, Cavaignac M, Hirsch TZ, Pire A, Imbeaud S, Morcrette G, Zhu C, Cadiou M, Marmier S, Elamouri Z, Aerts I, Chardot C, Sarnacki S, Taque S, Guettier C, Ferlicot S, Mussini C, Branchereau S, Fresneau B, Ronot M, Desdouets C, Nault JC, Zucman-Rossi J, Rebouissou S. J Hepatol. 2025. doi: 10.1016/j.jhep.2025.11.023.
- Human-correlated genetic models identify precision therapy for liver cancer.Müller M, May S, Hall H, Kendall TJ, McGarry L, Blukacz L, Nuciforo S, Georgakopoulou A, Jamieson T, Phinichkusolchit N, Dhayade S, Suzuki T, Huguet-Pradell J, Powley IR, Officer-Jones L, Pennie RL, Esteban-Fabró R, Gris-Oliver A, Pinyol R, Skalka GL, Leslie J, Hoare M, Sprangers J, Malviya G, Mackintosh A, Johnson E, McCain M, Halpin J, Kiourtis C, Nixon C, Clark G, Clark W, Shaw R, Hedley A, Drake TM, Tan EH, Neilson M, Murphy DJ, Lewis DY, Reeves HL, Le Quesne J, Mann DA, Carlin LM, Blyth K, Llovet JM, Heim MH, Sansom OJ, Miller CJ, Bird TG. Nature 2025. DOI: 10.1038/s41586-025-08585-z.
- Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, Gruttadauria S, Iavarone M, Mazzarelli C, Simonotti N, Yao F, Mazzaferro V, Llovet JM. JHEP Reports 2025. DOI: 10.1016/j.jhepr.2024.101246.
- Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced HCC. Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeitlhoefler M, Mesropian A, Huguet-Pradell J, Haber P K, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D’Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt UJ, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatic S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, Llovet JM. J Hepatol 2025. DOI: 10.1016/j.jhep.2024.12.016.
- Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim G, Kim C, Chon HJ. Liver Cancer. 2025. doi: 10.1159/000549565.
2024
-
- Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma. Roehrig A, Hirsch TZ, Pire A, Morcrette G, Gupta B, Marcaillou C, Imbeaud S, Chardot C, Gonzales E, Jacquemin E, Sekiguchi M, Takita J, Nagae G, Hiyama E, Guérin F, Fabre M, Aerts I, Taque S, Laithier V, Branchereau S, Guettier C, Brugières L, Fresneau B, Zucman-Rossi J, Letouzé E. Nat Commun 2024. DOI: 10.1038/s41467-024-47280-x.
- Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.Pire A, Hirsch TZ, Morcrette G, Imbeaud S, Gupta B, Pilet J, Cornet M, Fabre M, Guettier C, Branchereau S, Brugières L, Guerin F, Laithier V, Coze C, Nagae G, Hiyama E, Laurent-Puig P, Rebouissou S, Sarnacki S, Chardot C, Capito C, Faure-Conter C, Aerts I, Taque S, Fresneau B, Zucman-Rossi J. Eur J Cancer 2024. DOI: 10.1016/j.ejca.2024.113583.
- A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, Heikenwalder M. Cell Metab 2024. DOI: 10.1016/j.cmet.2024.04.015.
- HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx.Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier M-L, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng C-C, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Heikenwalder M. JHEP Reports 2024. DOI: 10.1016/j.jhepr.2024.101128.
- Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.Piqué-Gili M, Andreu-Oller C, Mesropian A, Esteban-Fabró R, Bárcena-Varela M, Ruiz de Galarreta M, Montironi C, Martinez-Quetglas I, Cappuyns S, Peix J, Keraite I, Gris-Oliver A, Fernández-Martínez E, Mauro E, Torres-Martin M, Abril-Fornaguera J, Lindblad KE, Lambrechts D, Dekervel J, Thung S, Sia D, Lujambio A, Pinyol R, Llovet JM. JHEP Reports 2024. DOI: 10.1016/j.jhepr.2024.101212.
- Single-cell profiling of intrahepatic immune cells reveals an expansion of tissue-resident cytotoxic CD4+ T lymphocyte subset associated with pathogenesis of alcoholic-associated liver diseases.Gao C, Wang S, Xie X, Ramadori P, Li X, Liu X, Ding X, Liang J, Xu B, Feng Y, Tan X, Wang H, Zhang Y, Zhang H, Zhang T, Mi P, Li S, Zhang C, Yuan D, Heikenwalder M, Zhang P. Cell Mol Gastroenterol Hepatol 2024. DOI: 10.1016/j.jcmgh.2024.101411.
- Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome.Gallage S, Irvine EE, Barragan Avila JE, Reen V, Pedroni SMA, Duran I, Ranvir V, Khadayate S, Pombo J, Brookes S, Heide D, Dharmalingham G, Choudhury AI, Singh I, Herranz N, Vernia S, Heikenwalder M, Gil J, Withers DJ. Nat Aging 2024. DOI: 10.1038/s43587-024-00695-z.
- Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma. Roehrig A, Hirsch TZ, Pire A, Morcrette G, Gupta B, Marcaillou C, Imbeaud S, Chardot C, Gonzales E, Jacquemin E, Sekiguchi M, Takita J, Nagae G, Hiyama E, Guérin F, Fabre M, Aerts I, Taque S, Laithier V, Branchereau S, Guettier C, Brugières L, Fresneau B, Zucman-Rossi J, Letouzé E. Nat Commun 2024. DOI: 10.1038/s41467-024-47280-x.
2023
-
- Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma. Pilet J, Hirsch TZ, Gupta B, Roehrig A, Morcrette G, Pire A, Letouzé E, Fresneau B, Taque S, Brugières L, Branchereau S, Chardot C, Aerts I, Sarnacki S, Fabre M, Guettier C, Rebouissou S, Zucman-Rossi J. Nat Commun 2023. DOI: 10.1038/s41467-023-42418-9.
- Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma. Pilet J, Hirsch TZ, Gupta B, Roehrig A, Morcrette G, Pire A, Letouzé E, Fresneau B, Taque S, Brugières L, Branchereau S, Chardot C, Aerts I, Sarnacki S, Fabre M, Guettier C, Rebouissou S, Zucman-Rossi J. Nat Commun 2023. DOI: 10.1038/s41467-023-42418-9.
Reviews and Guidelines:
2026
- Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis. Trépo E, Zucman-Rossi J, Nault JC. Nat Rev Gastroenterol Hepatol 2026. doi: 10.1038/s41575-026-01175-y
2025
-
- The gut microbiome connects nutrition and human health. Sanz Y, Cryan J, Deschasaux M, Elinav E, Lambrecht R, Veiga P. Nat Rev Gastroenterol Hepatol 2025. DOI: 10.1038/s41575-025-01077-5.
- Immune exclusion in hepatoblastoma: is β-catenin to blame again? Hirsch TZ. J Hepatol 2025. DOI: 10.1016/j.jhep.2025.05.005.
- Diet-Microbiome Interactions in Cancer. Abdeen SK, Mastandrea I, Stinchcombe N, Puschhof J, Elinav E. Cancer Cell 2025. DOI: 10.1016/j.ccell.2025.03.013.
- Shooting for the stars: caspase-8-meteorin in MASH and fibrosis. Gallage S, Bieler T, Heikenwalder M. Nat Metab. 2025 Oct;7(10):1965-1967. doi: 10.1038/s42255-025-01361-3. PMID: 41006903.
- The gut microbiome connects nutrition and human health. Sanz Y, Cryan J, Deschasaux M, Elinav E, Lambrecht R, Veiga P. Nat Rev Gastroenterol Hepatol 2025. DOI: 10.1038/s41575-025-01077-5.
2024
- Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Nat Rev Clin Oncol 2024. DOI: 10.1038/s41571-024-00868-0.
- Two decades of advances in clinical oncology — lessons learned and future directions. Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Weichselbaum RR, Weller M, Wu Y-L. Nat Rev Clin Oncol 2024. DOI: 10.1038/s41571-024-00945-4.
- Modeling cancer-microbiome interactions in vitro: A guide to co-culture platforms. Moskal K, Khurana N, Siegert L, Lee YS, Clevers H, Elinav E, Puschhof J. Int J Cancer 2024. DOI: 10.1002/ijc.35298.